UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months. However, resistance often occurs, largely limits its efficacy. Sorafenib was found to target the elect...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Junjie, Ji, Lin, Ruan, Yeling, Wan, Zhe, Lin, Zhongjie, Xia, Shunjie, Tao, Liye, Zheng, Junhao, Cai, Liuxin, Wang, Yifan, Liang, Xiao, Cai, Xiujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129126/
https://www.ncbi.nlm.nih.gov/pubmed/34001851
http://dx.doi.org/10.1038/s41392-021-00594-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129126/
https://www.ncbi.nlm.nih.gov/pubmed/34001851
http://dx.doi.org/10.1038/s41392-021-00594-4

Ejemplares similares